Pediatric respiratory medicine

References

• Government of Canada. Coronavirus disease 2019 (COVID-19): Epidemiology update [Internet]. 2020. [cited 2020 Dec 18]. Web site: https://health-infobase.canada.ca/covid-19/epidemiological-summary-covid-19-cases.html.
   Google Scholar
• Zimmermann P, Curtis N. Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. Arch Dis Child. 2020; 320338. Online ahead of print.
   Web of Science ®Google Scholar
• Statistics Canada. COVID-19 mortality rates in Canada’s ethno-cultural neighbourhoods [Internet]. 2020. [cited 2020 Dec 18]. Web site: https://www150.statcan.gc.ca/n1/pub/45-28-0001/2020001/article/00079-eng.htm.
   Google Scholar
• Zimmermann P, Curtis N. COVID-19 in Children, Pregnancy and Neonates: A Review of Epidemiologic and Clinical Features. Pediatr Infect Dis J. 2020;39(6):469–477. doi:10.1097/INF.0000000000002700.
   PubMed Web of Science ®Google Scholar
• Perikleous E, Tsalkidis A, Bush A, Paraskakis E. Coronavirus global pandemic: An overview of current findings among pediatric patients. Pediatr Pulmonol. 2020;55(12):3252–3267. doi:10.1002/ppul.25087.
   Web of Science ®Google Scholar
• Castagnoli R, Votto M, Licari A, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review. JAMA Pediatr. 2020;174(9):882–889. Sep 1doi:10.1001/jamapediatrics.2020.1467.
   PubMed Web of Science ®Google Scholar
• Canadian Pediatric Society. Interim CPSP results find that children are at lower risk of severe disease from acute SARS-CoV-2 (COVID-19) [Internet]. 2020. [cited 2020 Dec 18]. Web site: https://www.cps.ca/en/media/interim-cpsp-results-find-that-children-are-at-lower-risk-of-severe-disease-from-acute-covid-19.
   Google Scholar
• McClenaghan E, Cosgriff R, Brownlee K, Global Registry Harmonization Group, et al. The global impact of SARS-CoV-2 in 181 people with cystic fibrosis. J Cyst Fibros. 2020;19(6):868–871. doi:10.1016/j.jcf.2020.10.003.
   Web of Science ®Google Scholar
• Abrams EM, Sinha I, Fernandes RM, Hawcutt DB. Pediatric asthma and COVID-19: The known, the unknown, and the controversial. Pediatr Pulmonol. 2020;55(12):3573–3578. Oct 15; doi:10.1002/ppul.25117.
   PubMed Web of Science ®Google Scholar
• Moeller A, Thanikkel L, Duijts L, et al. COVID-19 in children with underlying chronic respiratory diseases: survey results from 174 centres. ERJ Open Res. 2020;6(4):00409-2020. Octdoi:10.1183/23120541.00409-2020.
   Google Scholar
• World Heatlh Organization. Multisystem inflammatory syndrome in children and adolescents with COVID-19 [Internet]. 2020. [cited 2020 Dec 18]. Web site: https://www.who.int/publications/i/item/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19.
   Google Scholar
• Center for Disease Control and Prevention. Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with Coronavirus Disease 2019 (COVID-19) [Internet]. 2020. [cited 2020 Dec 18]. Web site: https://emergency.cdc.gov/han/2020/han00432.asp.
   Google Scholar
• Panigrahy N, Policarpio J, Ramanathan R. Multisystem inflammatory syndrome in children and SARS-CoV-2: A scoping review. J Pediatr Rehabil Med. 2020;13(3):301–316. doi:10.3233/PRM-200794.
   Web of Science ®Google Scholar
• Beydon N, Gochicoa L, Jones MJ, et al. Pediatric lung function testing during a pandemic: An international perspective. Paediatr Respir Rev. 2020;36:106–108. Novdoi:10.1016/j.prrv.2020.10.001.
   Web of Science ®Google Scholar
• Davies JC, Wainwright CE, Sawicki GS, et al. Ivacaftor in Infants Aged 4 to <12 Months With Cystic Fibrosis and a Gating Mutation: Results of a 2-Part Phase 3 Clinical Trial. Am J Respir Crit Care Med. 2021;203(5):585–593.
   Web of Science ®Google Scholar
• Davies JC, Sermet-Gaudelus I, Naehrlich L, et al. A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation. J Cyst Fibros off J Eur Cyst Fibros Soc. 2021;20(1):68–77.
   Google Scholar
• Griese M, Costa S, Linnemann RW, et al. Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for ≥24 Weeks in People With CF and ≥1 F508del Allele: Interim Results of an Open-Label Phase Three Clinical Trial. Am J Respir Crit Care Med. 2021;203(3):381–385. doi:10.1164/rccm.202008-3176LE.
   PubMed Web of Science ®Google Scholar
• Sergeev V, Chou FY, Lam GY, Hamilton CM, Wilcox PG, Quon BS. The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis. Ann Am Thorac Soc. 2020;17(2):147–154. doi:10.1513/AnnalsATS.201909-671CME.
   PubMed Web of Science ®Google Scholar
• Bell SC, Mall MA, Gutierrez H, et al. The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2020;8(1):65–124. doi:10.1016/S2213-2600(19)30337-6.
   PubMed Web of Science ®Google Scholar
• Nichols DP, Odem-Davis K, Cogen JD, et al. Pulmonary Outcomes Associated with Long-Term Azithromycin Therapy in Cystic Fibrosis. Am J Respir Crit Care Med. 2020;201(4):430–437. 15doi:10.1164/rccm.201906-1206OC.
   PubMed Web of Science ®Google Scholar
• Kalaitzis IS, Rowbotham NJ, Smith SJ, Smyth AR. Do current clinical trials in cystic fibrosis match the priorities of patients and clinicans? A systematic review. J Cyst Fibros. 2020;19(1):26–33. Jandoi:10.1016/j.jcf.2019.06.005.
   Web of Science ®Google Scholar
• Davies G, Rowbotham NJ, Smith S, et al. Characterising burden of treatment in cystic fibrosis to identify priority areas for clinical trials. J Cyst Fibros. 2020;19(3):499–502. doi:10.1016/j.jcf.2019.10.025.
   Web of Science ®Google Scholar
• Forno E, Bacharier LB, Phipatanakul W, et al. Effect of Vitamin D3 Supplementation on Severe Asthma Exacerbations in Children With Asthma and Low Vitamin D Levels: The VDKA Randomized Clinical Trial. JAMA. 2020;324(8):752–760. doi:10.1001/jama.2020.12384.
   PubMed Web of Science ®Google Scholar
• Jat KR, Goel N, Gupta N, et al. Efficacy of vitamin D supplementation in asthmatic children with vitamin D deficiency: A randomized controlled trial (ESDAC trial). Pediatr Allergy Immunol off Publ Eur Soc Pediatr Allergy Immunol. 2021;32(3):479–488.
   Google Scholar
• Litonjua AA, Carey VJ, Laranjo N, et al. Effect of Prenatal Supplementation With Vitamin D on Asthma or Recurrent Wheezing in Offspring by Age 3 Years: The VDAART Randomized Clinical Trial. JAMA. 2016;315(4):362–370. doi:10.1001/jama.2015.18589.
   PubMed Web of Science ®Google Scholar
• Litonjua AA, Carey VJ, Laranjo N, et al. Six-Year Follow-up of a Trial of Antenatal Vitamin D for Asthma Reduction. N Engl J Med. 2020;382(6):525–533. doi:10.1056/NEJMoa1906137.
   Web of Science ®Google Scholar
• Schuh S, Sweeney J, Rumantir M, Pediatric Emergency Research Canada (PERC) Network, et al. Effect of Nebulized Magnesium vs Placebo Added to Albuterol on Hospitalization Among Children With Refractory Acute Asthma Treated in the Emergency Department: A Randomized Clinical Trial. JAMA. 2020;324(20):2038–2047. doi:10.1001/jama.2020.19839.
   Web of Science ®Google Scholar
• Gupta A, Pouliquen I, Austin D, et al. Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma. Pediatr Pulmonol. 2019;54(12):1957–1967. doi:10.1002/ppul.24508.
   PubMed Web of Science ®Google Scholar
• Gupta A, Ikeda M, Geng B, et al. Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype. J Allergy Clin Immunol. 2019;144(5):1336–1342.e7. doi:10.1016/j.jaci.2019.08.005.
   PubMed Web of Science ®Google Scholar